{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:30:44Z","timestamp":1786649444251,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Malignant pleural effusion (MPE) is a common complication of advanced cancer that impairs quality of life. The present study compared the outcomes of three procedures: tube thoracostomy with talc pleurodesis, video-assisted thoracoscopic surgery (VATS) with talc and indwelling pleural catheter (IPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 76 MPE patients were assigned to tube + talc (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 29), VATS + talc (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 27) or IPC (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20). Outcomes included pleurodesis success, complications, hospitalisation, 30-day reintervention, mortality and overall survival. Eastern Cooperative Oncology Group (ECOG) performance score and serum albumin were analysed as prognostic factors using Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      IPC had the shortest hospital stay (3 days) and the highest 30-day reintervention rate (20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.030). Pleurodesis success was 84.6% in both the tube and VATS groups. Median survival differed among groups (66 days for IPC, 95 days for tube and 118 days for VATS;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041); however, procedure type was not an independent predictor of survival, and these differences should be interpreted cautiously. ECOG \u22652 (hazard ratio [HR]: 1.74,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.020) and albumin &lt;3.0 g\/dL (HR: 1.60,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.040) were identified as independent predictors of poorer survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment selection should primarily be based on functional and nutritional status rather than expected survival benefit. ECOG performance status and serum albumin levels should play a central role in guiding individualised management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jmas.jmas_487_25","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:02:49Z","timestamp":1776067369000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of video-assisted thoracoscopic surgery, talc pleurodesis and indwelling catheterisation for malignant pleural effusion: A retrospective comparative study"],"prefix":"10.4103","author":[{"given":"Turkan","family":"Dubus","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Hamidiye Faculty of Medicine, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman Bagatur","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Kanuni Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokce","family":"Cangel","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sultangazi Haseki Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Ceyran","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/thorax-2023-220304","article-title":"British Thoracic Society Guideline for pleural disease","volume":"78","author":"Roberts","year":"2023","journal-title":"Thorax"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"1053574","DOI":"10.3389\/fonc.2022.1053574","article-title":"Malignant pleural effusion:Updates in diagnosis, management and current challenges","volume":"12","author":"Addala","year":"2022","journal-title":"Front Oncol"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.3390\/curroncol31110507","article-title":"Malignant pleural effusion:Diagnosis and treatment-up-to-date perspective","volume":"31","author":"Orlandi","year":"2024","journal-title":"Curr Oncol"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2019.09.003","article-title":"Survival in patients with malignant pleural effusion undergoing talc pleurodesis","volume":"137","author":"Hassan","year":"2019","journal-title":"Lung Cancer"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/diagnostics12041016","article-title":"Diagnosis and management of malignant pleural effusion:A decade in review","volume":"12","author":"Jacobs","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17476348.2024.2375421","article-title":"Advances in the diagnosis and follow-up of pleural lesions:A scoping review","volume":"18","author":"Panou","year":"2024","journal-title":"Expert Rev Respir Med"},{"issue":"Suppl 5","key":"R7-20260413","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter versus talc pleurodesis on hospitalization days in patients with malignant pleural effusion:The AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"JAMA"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter versus chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion:The TIME2 randomized controlled trial","volume":"307","author":"Davies","year":"2012","journal-title":"JAMA"},{"key":"R10-20260413","first-page":"CD010529","article-title":"Interventions for the management of malignant pleural effusions:A network meta-analysis","volume":"4","author":"Dipper","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion:From bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur Respir Rev"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion:Tumor-host interactions unleashed","volume":"186","author":"Stathopoulos","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-20260413","first-page":"115","article-title":"Malignant pleural effusions:Updates in diagnosis and management","volume":"13","author":"Hughes","year":"2023","journal-title":"Life (Basel)"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5606\/tgkdc.dergisi.2021.20580","article-title":"Surgical treatment in malignant pleural effusion","volume":"29","author":"Karaday\u0131\u015e","year":"2021","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1716883","article-title":"Outpatient talc administration by indwelling pleural catheter for malignant effusion","volume":"378","author":"Bhatnagar","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"738719","DOI":"10.3389\/fsurg.2021.738719","article-title":"Ambulatory thoracoscopic pleurodesis combined with indwelling pleural catheter in malignant pleural effusion","volume":"8","author":"Foo","year":"2021","journal-title":"Front Surg"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000491934","article-title":"The hospital and patient burden of indwelling pleural catheters:A retrospective case series of 210 indwelling pleural catheter insertions","volume":"97","author":"Asciak","year":"2019","journal-title":"Respiration"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1378\/chest.129.2.362","article-title":"Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion","volume":"129","author":"Tremblay","year":"2006","journal-title":"Chest"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/medicina55080490","article-title":"Malignant pleural effusion and its current management:A review","volume":"55","author":"Skok","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/lungindia.lungindia_633_21","article-title":"The role of LENT and PROMISE scores in predicting survival in malignant pleural effusion","volume":"39","author":"Ermin","year":"2022","journal-title":"Lung India"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1002\/ctm2.774","article-title":"A novel nano-immunotherapeutic remodels the immune landscape of malignant pleural effusion:Insights into its mechanism of action through single-cell RNA-sequencing","volume":"12","author":"Liu","year":"2022","journal-title":"Clin Transl Med"}],"container-title":["Journal of Minimal Access Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmas.jmas_487_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:15Z","timestamp":1786647255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmas.jmas_487_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.4103\/jmas.jmas_487_25","relation":{},"ISSN":["0972-9941","1998-3921"],"issn-type":[{"value":"0972-9941","type":"print"},{"value":"1998-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"2025-11-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}